|
293 Companies |
|
491 Products |
|
491 Products |
|
198 Mechanisms of Action |
|
26 Trials |
|
7805 News |
|
| «12...2021222324252627282930...156157» |
- |||| Trial completion, Adherence: Mobile Technology & Online Tools to Track Adherence in Chronic Illness Patients (clinicaltrials.gov) - Jan 30, 2017
P2, N=200, Completed, Sponsor: 3-C Institute for Social Development
Active, not recruiting --> Completed
- New trial: Suspending Basal Insulin Levels for Exercise in Adults With Type 1 Diabetes (clinicaltrials.gov) - Jan 30, 2017
P=N/A, N=12, Completed, Sponsor: York University
- Zinbryta (daclizumab) / Biogen, AbbVie
Trial completion: Human Anti-Tac (Daclizumab) to Treat Juvenile Idiopathic Arthritis (JIA)-Associated Uveitis (clinicaltrials.gov) - Jan 29, 2017
P2, N=6, Completed, Sponsor: National Eye Institute (NEI)
Active, not recruiting --> Completed Recruiting --> Completed
- ||||||| Levemir (insulin detemir rDNA origin) / Novo Nordisk
Trial completion: Safety and Efficacy of Insulin Detemir Plus Insulin Aspart Against Insulin Glargine Plus Insulin Aspart as Mealtime Insulin in Type 1 Diabetes (clinicaltrials.gov) - Jan 29, 2017
P3, N=447, Completed, Sponsor: Novo Nordisk A/S
Recruiting --> Completed No longer recruiting --> Completed
- Trial termination: EMR200109_635: Vitamin D3 and the Stress-axis in MS (clinicaltrials.gov) - Jan 26, 2017
P2, N=54, Terminated, Sponsor: Academic MS Center Limburg
No longer recruiting --> Completed Active, not recruiting --> Terminated; difficulties with inclusion
- Trial completion, Enrollment change, Trial primary completion date: NIGA-RA: Multicenter Study Evaluating the Performance of the Assay of Anti-hinge Region Antibodies in the Diagnosis of Progressive Forms of IgA Nephropathy (clinicaltrials.gov) - Jan 26, 2017
P=N/A, N=68, Completed, Sponsor: Centre Hospitalier Universitaire de Saint Etienne
Active, not recruiting --> Terminated; difficulties with inclusion Recruiting --> Completed | N=120 --> 68 | Trial primary completion date: Sep 2016 --> Jun 2014
- ||||| Lupuzor (rigerimod) / ImmuPharma, Alora Pharma
Trial initiation date, Trial primary completion date: A 52-Week, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a 200-mcg Dose of IPP-201101 Plus Standard of Care in Patients With Systemic Lupus Erythematosus (clinicaltrials.gov) - Jan 26, 2017
P3, N=200, Active, not recruiting, Sponsor: ImmuPharma
Recruiting --> Completed | N=120 --> 68 | Trial primary completion date: Sep 2016 --> Jun 2014 Initiation date: Dec 2015 --> Mar 2015 | Trial primary completion date: Jun 2017 --> Mar 2018
- Enrollment closed: Pre-POINT-Early Study (clinicaltrials.gov) - Jan 26, 2017
P2, N=44, Active, not recruiting, Sponsor: Technische Universit
Initiation date: Dec 2015 --> Mar 2015 | Trial primary completion date: Jun 2017 --> Mar 2018 Recruiting --> Active, not recruiting
- Basalin (insulin glargine biosimilar) / Gan & Lee Pharma, LG Chem, Sandoz
Trial completion: PK/PD Study of Gan & Lee's Insulin Glargine Injection in Comparison to Lantus in Type 1 Diabetes (clinicaltrials.gov) - Jan 26, 2017
P1, N=41, Completed, Sponsor: Gan and Lee Pharmaceuticals, USA
Recruiting --> Active, not recruiting Recruiting --> Completed
- Trial initiation date, Trial primary completion date: A Study to Evaluate the Safety, Mode of Action and Clinical Efficacy of GSK3050002 in Subjects With Psoriatic Arthritis (clinicaltrials.gov) - Jan 26, 2017
P1, N=18, Not yet recruiting, Sponsor: GlaxoSmithKline
Recruiting --> Completed Initiation date: Feb 2016 --> Jun 2017 | Trial primary completion date: Jul 2017 --> Aug 2018
- Kineret (anakinra) / SOBI
Trial completion, Enrollment change: Anti-IL-1 Treatment in Children Diabetic Keto-Acidosis (DKA) at Diagnosis of Type 1 Diabetes (clinicaltrials.gov) - Jan 24, 2017
P2, N=1, Completed, Sponsor: University of Colorado, Denver
Initiation date: Feb 2016 --> Jun 2017 | Trial primary completion date: Jul 2017 --> Aug 2018 Suspended --> Completed | N=21 --> 1
- | Betaseron (IFN-β-1b) / Bayer
Phase classification, HEOR: BetaSleep: Investigating the Relationship Between Sleep, Quality of Life,Other Disorders and Therapies in MS Patients on Betaferon (clinicaltrials.gov) - Jan 24, 2017
P=N/A, N=138, Active, not recruiting, Sponsor: Bayer
Suspended --> Completed | N=21 --> 1 Phase classification: P4 --> P=N/A
- Kesimpta (ofatumumab subcutaneous) / Novartis, Genmab
Trial primary completion date: Long-Term Extension Study of Ofatumumab in Subjects With Pemphigus Vulgaris (clinicaltrials.gov) - Jan 24, 2017
P3, N=1, Terminated, Sponsor: GlaxoSmithKline
Phase classification: P4 --> P=N/A Trial primary completion date: Feb 2020 --> Mar 2016
- | Trial completion, Trial primary completion date: FACT-CGM: Factors in Accuracy Studies Influencing Measured CGM Performance. (clinicaltrials.gov) - Jan 24, 2017
P=N/A, N=21, Completed, Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Trial primary completion date: Feb 2020 --> Mar 2016 Recruiting --> Completed | Trial primary completion date: Oct 2016 --> Jan 2017
- || Enrollment change: Prospective Outcomes Study: Vectra® DA Guided Care Compared to Usual Care (clinicaltrials.gov) - Jan 23, 2017
P=N/A, N=318, Recruiting, Sponsor: Crescendo Bioscience
Recruiting --> Completed | Trial primary completion date: Oct 2016 --> Jan 2017 N=265 --> 318
- Zostavax (zoster vaccine live) / Merck (MSD)
Trial primary completion date: Safety and Effectiveness Study of the Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users (VERVE) (clinicaltrials.gov) - Jan 23, 2017
P2, N=125, Active, not recruiting, Sponsor: University of Alabama at Birmingham
N=265 --> 318 Trial primary completion date: Dec 2016 --> Apr 2017
- nifedipine immediate release / Generic mfg.
New trial: Topical 10 % Nifedipine Versus 5% Sildenafil in Secondary Raynaud (clinicaltrials.gov) - Jan 23, 2017
P=N/A, N=10, Completed, Sponsor: Pontificia Universidad Catolica de Chile
- Trial completion: The Effects of a Six-week Exercise Programme Undertaken by Women With Rheumatoid Arthritis (clinicaltrials.gov) - Jan 19, 2017
P=N/A, N=25, Completed, Sponsor: Siobhan Graham
Trial primary completion date: Dec 2016 --> Apr 2017 Active, not recruiting --> Completed
- || Enrollment closed, Trial primary completion date: Threshold Suspend in Pediatrics at Home (clinicaltrials.gov) - Jan 19, 2017
P=N/A, N=300, Active, not recruiting, Sponsor: Medtronic Diabetes
Active, not recruiting --> Completed Enrolling by invitation --> Active, not recruiting | Trial primary completion date: Mar 2017 --> Jun 2017
- Enrollment change: Multiple Sclerosis: Associated Cardiometabolic Risks and Impact of Exercise Therapy (clinicaltrials.gov) - Jan 19, 2017
P=N/A, N=110, Completed, Sponsor: Bert Op't Eijnde
Enrolling by invitation --> Active, not recruiting | Trial primary completion date: Mar 2017 --> Jun 2017 N=80 --> 110
- ||||| tofacitinib / Generic mfg.
Head-to-Head: A Study To Evaluate The Safety And Efficacy Of Tofacitinib Modified Release Tablets Compared To Tofacitinib Immediate Release Tablets In Adult Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Jan 19, 2017
P3, N=200, Active, not recruiting, Sponsor: Pfizer
N=80 --> 110 Recruiting --> Active, not recruiting
- Trial completion: Respiratory Function and Walking Capacity in Multiple Sclerosis (clinicaltrials.gov) - Jan 18, 2017
P=N/A, N=50, Completed, Sponsor: Region Örebro County
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||||||| Cimzia (certolizumab pegol) / Astellas, UCB
Trial completion: RAPID-C OLE: An Open-label Extension Study of Certolizumab Pegol in Chinese Patients With Rheumatoid Arthritis Who Enrolled in RA0044 (clinicaltrials.gov) - Jan 18, 2017
P3, N=347, Completed, Sponsor: UCB Pharma SA
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | autologous hematopoietic stem cell therapy / Northwestern University
Trial completion: Safety and Efficacy Study of Autologous Stem Cell Transplantation for Early Onset Type I Diabetes Mellitus (clinicaltrials.gov) - Jan 18, 2017
P1/2, N=25, Completed, Sponsor: University of Sao Paulo
Active, not recruiting --> Completed Recruiting --> Completed
- namilumab (IZN-101) / Amgen, Izana Biosci, Roivant
Biomarker: Blood Sample Collection Study for Pharmacogenomic Characterization of Participants That Previously Received Namilumab in M1-1188-002-EM (PRIORA, [NCT01317797]) Study (clinicaltrials.gov) - Jan 18, 2017
P1, N=8, Completed, Sponsor: Takeda
Recruiting --> Completed N=14 --> 8
- ||| Orencia (abatacept) / BMS
Trial completion, Trial initiation date: Survey on Long-Term Use of ORENCIA® Intravenous Infusion 250mg (clinicaltrials.gov) - Jan 17, 2017
P=N/A, N=671, Completed, Sponsor: Bristol-Myers Squibb
N=14 --> 8 Active, not recruiting --> Completed | Initiation date: Jul 2011 --> Sep 2013
- New trial: Evaluation of the EarEEG System for Detection of Hypoglycaemia-induced Changes in the EEG in Subjects With Type 1 Diabetes (clinicaltrials.gov) - Jan 17, 2017
P=N/A, N=20, Not yet recruiting, Sponsor: Odense University Hospital
- || Clinical data, Enrollment closed, Observational data, Real-world evidence, Real-world: EFFECT: Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS) (clinicaltrials.gov) - Jan 13, 2017
P=N/A, N=2978, Active, not recruiting, Sponsor: Biogen
Active, not recruiting --> Completed | Initiation date: Jul 2011 --> Sep 2013 Recruiting --> Active, not recruiting
- ||| Orencia (abatacept) / BMS
Trial completion, Enrollment change, Trial primary completion date: Use-Results Survey for ORENCIA® Subcutaneous Injection 125mg Syringe 1mL (clinicaltrials.gov) - Jan 13, 2017
P=N/A, N=505, Completed, Sponsor: Bristol-Myers Squibb
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | N=370 --> 505 | Trial primary completion date: Sep 2016 --> Jun 2016
- | Trial completion, Enrollment change, Trial primary completion date: Closed-Loop Control in Young Children 5-8 Years Old Using DiAs Platform (clinicaltrials.gov) - Jan 13, 2017
P=N/A, N=12, Completed, Sponsor: University of Virginia
Active, not recruiting --> Completed | N=370 --> 505 | Trial primary completion date: Sep 2016 --> Jun 2016 Recruiting --> Completed | N=24 --> 12 | Trial primary completion date: Dec 2016 --> May 2016
- Firdapse (amifampridine) / BioMarin, Catalyst Pharma
Enrollment status: Phase 3 Study to Evaluate Efficacy of Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS) (clinicaltrials.gov) - Jan 12, 2017
P3, N=28, Recruiting, Sponsor: Catalyst Pharmaceuticals, Inc.
Recruiting --> Completed | N=24 --> 12 | Trial primary completion date: Dec 2016 --> May 2016 Enrolling by invitation --> Recruiting
- Enrollment change: Telemetric Glucose Data Acquisition During Initiation of Insulin Pump Therapy (clinicaltrials.gov) - Jan 12, 2017
P2, N=0, Withdrawn, Sponsor: Thomas Jefferson University
Enrolling by invitation --> Recruiting N=32 --> 0
- New trial: Continuous Glucose Monitoring on Patients With Active Autoimmune Diseases Following High-dose Predisone Treatment (clinicaltrials.gov) - Jan 12, 2017
P=N/A, N=25, Completed, Sponsor: Peking Union Medical College Hospital
- | Trial completion, Enrollment change: Long Term Treatment Effect of the Safety, Tolerability and Efficacy of AAT in Type 1 Diabetes (clinicaltrials.gov) - Jan 11, 2017
P2, N=12, Completed, Sponsor: Rabin Medical Center
N=32 --> 0 Active, not recruiting --> Completed | N=24 --> 12
- ||| Trial completion, Enrollment change, Trial primary completion date: Prospective Study Measuring Clinical Outcomes of Knee Arthroplasty Using the VERASENSE (clinicaltrials.gov) - Jan 11, 2017
P=N/A, N=285, Completed, Sponsor: Orthosensor, Inc.
Active, not recruiting --> Completed | N=24 --> 12 Active, not recruiting --> Completed | N=500 --> 285 | Trial primary completion date: Aug 2016 --> Dec 2016
- | Trial completion, Enrollment change, Trial primary completion date: MD Logic Pump Advisor -Pediatric Study (clinicaltrials.gov) - Jan 11, 2017
P=N/A, N=25, Completed, Sponsor: Rabin Medical Center
Active, not recruiting --> Completed | N=500 --> 285 | Trial primary completion date: Aug 2016 --> Dec 2016 Recruiting --> Completed | N=80 --> 25 | Trial primary completion date: Sep 2016 --> Jan 2017
- Trial completion, Enrollment change: Overnight MD-Logic (clinicaltrials.gov) - Jan 11, 2017
P=N/A, N=151, Completed, Sponsor: Rabin Medical Center
Recruiting --> Completed | N=80 --> 25 | Trial primary completion date: Sep 2016 --> Jan 2017 Active, not recruiting --> Completed | N=263 --> 151
- | Trial completion, Enrollment change, Trial primary completion date: MD Logic Pump Advisor- Adults Study (clinicaltrials.gov) - Jan 11, 2017
P=N/A, N=18, Completed, Sponsor: Rabin Medical Center
Active, not recruiting --> Completed | N=263 --> 151 Active, not recruiting --> Completed | N=135 --> 18 | Trial primary completion date: Dec 2016 --> Jul 2016
- prezalumab (AMG 557) / Amgen, AstraZeneca
Phase classification, Trial primary completion date: A Phase 2a, Randomized, Placebo Controlled, Study to Evaluate the Safety and Efficacy of AMG 557/MEDI5872 in Primary Sj (clinicaltrials.gov) - Jan 11, 2017
P2a, N=42, Recruiting, Sponsor: MedImmune LLC
Active, not recruiting --> Completed | N=135 --> 18 | Trial primary completion date: Dec 2016 --> Jul 2016 Phase classification: P2 --> P2a | Trial primary completion date: Feb 2017 --> Jul 2017
- Trial completion, Enrollment change, Trial primary completion date: Development and Assessment of Feasibility of Non-invasive Multiple Sensor Hypo-Sense as a Tool for Detection of Hypoglycemia (clinicaltrials.gov) - Jan 11, 2017
P=N/A, N=3, Completed, Sponsor: Rabin Medical Center
Phase classification: P2 --> P2a | Trial primary completion date: Feb 2017 --> Jul 2017 Active, not recruiting --> Completed | N=20 --> 3 | Trial primary completion date: Dec 2016 --> Jul 2016
- |||| Litfulo (ritlecitinib) / Pfizer
Enrollment open: Study To Assess The Efficacy And Safety Of Pf-06651600 In Subjects With Rheumatoid Arthritis With An Inadequate Response To Methotrexate (clinicaltrials.gov) - Jan 11, 2017
P2a, N=60, Recruiting, Sponsor: Pfizer
Active, not recruiting --> Completed | N=20 --> 3 | Trial primary completion date: Dec 2016 --> Jul 2016 Not yet recruiting --> Recruiting
- |||| Tcelna (imilecleucel-T) / Acer Therap, EMD Serono
Trial completion: Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis (clinicaltrials.gov) - Jan 10, 2017
P2, N=183, Completed, Sponsor: Opexa Therapeutics, Inc.
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | oxcarbazepine / Generic mfg.
Enrollment change: PROXIMUS: Protective Role of Oxcarbazepine in Multiple Sclerosis (clinicaltrials.gov) - Jan 10, 2017
P2a, N=30, Recruiting, Sponsor: Queen Mary University of London
Active, not recruiting --> Completed N=60 --> 30
- |||| M923 (adalimumab biosimilar) / J&J
Trial primary completion date: Usability of an AI for M923 in Subjects With Moderate to Severe RA (clinicaltrials.gov) - Jan 10, 2017
P3, N=51, Active, not recruiting, Sponsor: Baxalta US Inc.
N=60 --> 30 Trial primary completion date: Dec 2016 --> Mar 2017
- | cyclophosphamide / Generic mfg.
Trial completion: Treating Systemic Lupus Erythematosus (SLE) Patients With CTLA4-IgG4m (RG2077) (clinicaltrials.gov) - Jan 10, 2017
P1/2, N=6, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Trial primary completion date: Dec 2016 --> Mar 2017 No longer recruiting --> Completed
- Hizentra (human immune globulin subcutaneous 20%) / CSL Behring
Trial primary completion date: SIMM: Subcutaneous Ig Maintenance Therapy for Myasthenia Gravis (clinicaltrials.gov) - Jan 10, 2017
P=N/A, N=4, Terminated, Sponsor: St. Louis University
No longer recruiting --> Completed Trial primary completion date: Dec 2016 --> Dec 2017
- Diamyd (recombinant 65 kDa isoform of human glutamic acid decarboxylase) / Diamyd Medical
Trial primary completion date, Combination therapy: DIABGAD - Trial to Preserve Insulin Secretion in Type 1 Diabetes Using GAD-Alum (Diamyd) in Combination With Vitamin D and Ibuprofen (clinicaltrials.gov) - Jan 10, 2017
P2, N=60, Active, not recruiting, Sponsor: Johnny Ludvigsson
Trial primary completion date: Dec 2016 --> Dec 2017 Trial primary completion date: Dec 2016 --> Mar 2017
- Orencia (abatacept) / BMS
P2 data, Trial primary completion date: Abatacept for Patients With Inflammatory Arthritis Associated With Sjögren's Syndrome: an Open-Label Phase II Study (clinicaltrials.gov) - Jan 9, 2017
P2, N=0, Withdrawn, Sponsor: The Cleveland Clinic
Trial primary completion date: Dec 2016 --> Mar 2017 Trial primary completion date: Apr 2015 --> Oct 2014
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Trial completion, Combination therapy: Bendamustine and Rituximab Combination Therapy for Cold Agglutinin Disease (clinicaltrials.gov) - Jan 9, 2017
P2, N=43, Completed, Sponsor: Helse Fonna
Trial primary completion date: Apr 2015 --> Oct 2014 Recruiting --> Completed
- | Phase classification: Observational Study of Patients Using NovoMix (clinicaltrials.gov) - Jan 9, 2017
P4, N=1569, Completed, Sponsor: Novo Nordisk A/S
Recruiting --> Completed Phase classification: P=N/A --> P4